申请人:Incyte Corporation
                            
                            
                                公开号:US20180282340A1
                            
                            
                                公开(公告)日:2018-10-04
                            
                            The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.